期刊
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
卷 184, 期 5, 页码 507-513出版社
AMER THORACIC SOC
DOI: 10.1164/rccm.201103-0405PP
关键词
diagnosis; epidemiology; inflammation; spirometry; systems biology
资金
- GlaxoSmithKline (GSK)
- Almirall
- Boehringer Ingelheim (BI)
- AstraZeneca (AZ)
- Esteve
- Novartis
- Nycomed
- Roche
- Chiesi Pharmaceuticals
- Pfizer
Over the past decade there has been much research and interest in COPD. As a result, the understanding and management of the disease has improved significantly. Yet, there are many uncertainties and controversies that require further work. This review discusses these controversies and anticipates some of the changes that may occur in the near future in the field of COPD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据